NanoViricides to Present at LSX World Congress in Boston

NanoViricides, Inc., a leader in clinical-stage antiviral drug development, is set to present at the Life Science Executive Partnering (LSX) World Congress on September 17, 2025, in Boston. Dr. Anil R. Diwan, the company's President and Executive Chairman, will provide updates on NanoViricides' drug pipeline and licensing technologies.

The company's most promising candidate, NV-387, is a broad-spectrum antiviral targeting various respiratory viruses. NV-387 is designed to emulate attachment receptors used by many human viruses, offering a potentially revolutionary approach to antiviral therapy akin to the advent of antibiotics.

NV-387 is advancing towards Phase II trials for treating MPOX, addressing a public health emergency recognized by the WHO. Additionally, it has demonstrated effectiveness against "tripledemic" viruses and shows promise in handling diseases like RSV, Smallpox, and Measles.